Kenvue

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Kenvue (KVUE) reports strong Q2 earnings, eyes China growth

Kenvue's Q2 performance showcased robust net sales, organic growth, and strategic investments in key segments. The company's focus on consumer trust, supply chain enhancements, and capital allocation strategy underpin its resilience. Challenges include managing inflationary pressures and sustaining growth post-COVID, but opportunities in China and ongoing investments position Kenvue for future success.

Kenvue (KVUE) reports solid Q3 performance amidst segment challenges

Kenvue (KVUE) delivered a solid Q3 performance, showcasing strength in key segments despite challenges in others.
The company's strategic initiatives, focus on innovation, and outlook for growth opportunities position it well for future success.
Efforts to address challenges in specific segments and capitalize on opportunities demonstrate a proactive approach to sustaining growth and profitability.
Overall positive outlook on third-quarter results reflects the company's strong model, portfolio, and cash flow generation capabilities.

Kenvue reports mixed 2023 performance, focuses on growth strategies

Kenvue's 2023 performance saw organic growth but faced challenges in specific segments, leading to adjustments for 2024. The company aims to drive growth through operational efficiencies, increased brand investments, and a focus on consumer engagement. Challenges in U.S. in-store execution prompted a recovery plan and leadership changes.

Kenvue surpasses Q1 expectations, eyes China growth amid challenges

Kenvue's Q1 performance exceeded expectations, driven by key segments and brands.
Strategic focus on cost optimization, operational efficiency, and brand impact.
Challenges include stabilizing declining segments and managing hyperinflation impact.
Opportunities lie in growing China business, operational reinvention, and new leadership.

Kenvue reports solid Q2 performance and optimistic outlook for 2024

Kenvue's Q2 performance reflects steady growth and improved profitability, driven by strategic initiatives and strong brand performance. While cost management and increased marketing spend pose challenges, the company's focus on brand investment and long-term value creation offers promising opportunities for future growth and shareholder returns.

Kenvue reports Q3 growth, tackles Skin Health challenges, eyes savings

Kenvue's Q3 performance showed organic growth and strong financial metrics.
While facing challenges in the Skin Health segment, the company is focusing on recovery.
Investments in marketing and efficiency improvements highlight growth opportunities.
Executives addressed key questions on guidance, inventory levels, and growth strategies.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Kenvue, Inc. is a consumer health company. It operates through the following business segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment includes cough, cold and allergy, pain care, digestive health, and smoking cessation. The Skin Health and Beauty segment offers face and body care and hair, sun and others. The Essential Health segment focuses on oral care, baby care, women's health and wound care. The company was founded on February 23, 2022 and is headquartered in Skillman, NJ.

Fortis

Hormel Foods

Altria

Northwest Natural Gas

United Bankshares

Universal Corp

Archer-Daniels-Midland Company

Black Hills

California Water Service Group

Coca-Cola

Middlesex Water

National Fuel Gas

SJW Group

Stanley Black & Decker

"What is a Dividend King? A stock with 50 or more consecutive years of dividend increases."—suredividend.com. The 53 Dividend Kings, screened as of July 8, represented 8 of 11 Morningstar Sectors. Broker-targeted top-ten net-gains ranged 18.24%-30.31% topped-by Kenvue, and Genuine Parts. By yield, Altria tops-all. Top-ten July listings: SWK, FRT, KVUE, FTS, UBSI, BKH, NWN, CDUAF, UVV, MMM, & MO averaged 5.37% in yield.

53 July Dividend Kings: Buy 8, Watch 8 More

SKILLMAN, N.J.--(BUSINESS WIRE)--Kenvue will announce its financial results for the second quarter ending June 30, 2024, before market open on August 6, 2024.

Kenvue to Announce Second Quarter 2024 Results on August 6, 2024

American Electric Power Company

VanEck Vectors Oil Refiners ETF

Kenvue is less than 3% off its 52-week low, but the sell-off is a buying opportunity. Shares of dividend powerhouse American Electric Power are on a summer sale.

3 High-Yield Dividend Stocks/ETFs to Buy Hand Over Fist in July

AbbVie

Amcor Plc

Chevron

Kimberly-Clark

Realty Income Corp

Just 1% of all stocks listed on the major U.S. exchanges are Dividend Aristocrats. These are the 67 companies listed on the S&P 500 that have raised their dividends for 25 consecutive years or more.

7 Dividend Aristocrats That Will Have Investors in High-Yield Heaven

Estee Lauder

EPAM Systems

NIKE

PayPal

VeriSign

Is the market set to continue heading higher? Or after a tremendous run, are the bulls finally running out of steam?

7 S&P 500 Stocks to Buy on the Dip: June 2024

SKILLMAN, N.J.--(BUSINESS WIRE)--Kenvue shares progress on its Environmental, Social and Governance goals in its first-ever Healthy Lives Mission Report.

Kenvue Releases Inaugural Healthy Lives Mission Report

Cisco Systems

Verizon

Dividend investing is an attractive strategy for consistent income. And could reward investors with multiple dividend checks over a month span if structured properly. As a retiree who gets paid once on a monthly basis, dividend investing has allowed me to structure my payments, helping grow my dividend snowball at a faster pace. Verizon, Kenvue, and Cisco Systems offer well-covered dividends and potential upside for income-focused investors with a longer-term investment horizon.

Focused On Income? 3 Deep Value Stocks To Add To Your Portfolio

Johnson & Johnson

Rexford Industrial Realty

FOMO is driving stock market decisions, especially with meme stocks like GameStop and high-flying AI stocks. That's why I prefer discounted dividend stocks over growth stocks, and highlight two picks that offer durable capital returns. Both names carry strong balance sheets, pay well-above market average dividend yields, and are trading at substantial discounts to their historical valuations.

Two High Conviction Dividend Buys For This Upside-Down Market

Intuitive Surgical

Medtronic

Healthcare stocks offer a haven for investors amidst the uncertainty. The Fed elected to hold interest rates at a 23-year high between 5.25% and 5.5% to combat persistent inflation.

3 Healthcare Stocks to Buy Now: June 2024

Anheuser-Busch InBev

Federal Realty Investment Trust

While getting to retirement age can be a blessing and a curse, the reality of counting on the U.S.

5 Dividend Kings to Buy Now for Dependable Retirement Passive Income

Bristol-Myers

Dominion Energy

Rio Tinto plc Sponsored

24/7 Insights Quality dividend stocks can generate solid total returns and yield passive income.

6 of Wall Street's Favorite High-Yield Blue Chip Dividend Stocks to Buy in June

Franklin Resources

24/7 Insights Passive income is an easy way to supplement retirement and pension distributions.

5 Dividend Aristocrats Will Deliver Steady Passive Income During a Volatile Summer

Cleveland-Cliffs

Barrick Gold

Joby Aviation

Kinder Morgan

Nintendo

The May inflation readings showed cooling consumer and producer prices. However, in 2024, it's important to define the meaning of words.

The 7 Best Under $20 Stocks to Buy in June 2024

Kenvue (KVUE) was created as the result of a spinoff from Johnson & Johnson and encompasses the consumer side of the business. KVUE manages a wide array of products within each segment, but sales volume remains vulnerable to consumer spending. Data shows us that consumers are willing to go with store-branded generics as an alternative to name brands under KVUE's umbrella to save money.

Kenvue: Portfolio Of Products Can Be Replaced With Generic Brands

Kenvue is a stock with a 4.4% yield and potential for long-term growth as a result of their strong brands like Tylenol, Neutrogena, and Listerine. The company reported solid earnings and organic growth in a challenging environment. Kenvue's segments showed mixed results, with solid growth in two of its three segments.

Kenvue: A 4% Yield Worth Going Long

24/7 Insights: Investors looking for dividend safety love the Dividend Aristocrats The Dividend Aristocrats are the perfect vehicle to deliver passive income Access 2 legendary, high-yield dividend stocks Wall Street loves Investors love dividend stocks because they provide dependable income and a great opportunity for solid total return.

3 Dividend Aristocrats to Buy Today

SKILLMAN, N.J.--(BUSINESS WIRE)--Kenvue will participate in Deutsche Bank's dbAccess Global Consumer Conference in Paris, France.

Kenvue Announces Participation in Deutsche Bank's dbAccess Global Consumer Conference

Pfizer

It's a great time to be looking at healthcare stocks to buy now. According to research from BlackRock, U.S. healthcare stocks have outperformed the overall stock market by an average of 10% over the past seven recessions.

3 Healthcare Stocks to Buy Now: May 2024

WK Kellogg Co

Solventum Corporation

Too often spinoff stocks don't perform well out of the gate. Because an investor bought the business of the parent company, he doesn't care too much about whatever side project is being shed.

Divide and Conquer: 3 Stock Spinoffs Set to Trounce the Market

SKILLMAN, N.J.--(BUSINESS WIRE)--Kenvue Inc. (NYSE: KVUE) announced the pricing of its secondary underwritten public offering of 182,329,550 shares of its common stock.

Kenvue Announces Pricing of Secondary Offering

Kenvue (NYSE: KVUE ) stock is in the news Monday after the company announced that Johnson & Johnson (NYSE: JNJ ) is selling its stake in the business. Kenvue has announced a secondary offering that will have Johnson & Johnson selling its entire stake of 182,329,550 shares of KVUE stock.

Johnson & Johnson Is Officially Getting Out of Kenvue (KVUE) Stock

Kenvue Inc.'s stock fell 1.8% early Monday, after the consumer-health business, which was spun out of Johnson & Johnson last year, announced plans for a secondary offering of 182.3 million shares.

Kenvue's stock falls after company announces 182.3 million secondary stock offering

Tylenol maker Kenvue said on Monday that Johnson & Johnson will offload its entire 9.5% stake in the company, about a year after the healthcare conglomerate spun off and listed its consumer health business.

J&J to exit Kenvue, a year after spinoff

SKILLMAN, N.J.--(BUSINESS WIRE)--Kenvue announced today the launch of a secondary underwritten public offering of 182,329,550 shares of its common stock.

Kenvue Announces Launch of Secondary Offering

J. M. Smucker

Want retirement to come a few years earlier than you'd planned? Orare you ready to retire now, but want an extra set of eyes on your finances?

4 Strong Buy Dividend Aristocrats Wall Street Loves Are Trading Just Above 52-Week Lows

News for Kenvue Stock (KVUE)